Skip to main content
OpenTrials
Completed

NCT Number: NCT06083909

Sarcopenic Obesity in the Elderly

Ageing is associated with progressive and generalized loss of muscle mass and muscle function, also known as Sarcopenia. Increasingly, obesity has become a compounding factor in ageing-related sarcopenia. The coexistence of obesity and sarcopenia is termed sarcopenic obesity (SO). Older adults with SO are at higher risks of developing diabetes, hypertension, stroke, cardiovascular diseases, and cognitive dysfunction than those older adults who suffer from sarcopenia alone or obesity alone. However, there is insufficient information with regard to the interplay between obesity and sarcopenia. The primary objective of this study is to investigate the impact of SO on insulin resistance in people aged 65-85. Our hypothesis is that SO positively influences insulin resistance in the elderly. We propose to investigate sarcopenia and obesity as risk factors for insulin resistance in the geriatric (65-85 years old) population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenic Obesity Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

65 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Central Florida

Orlando, Florida, 32816, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

This study will include both male and females aged 65-85 years.

Exclusion criteria

  • Lack capacity to consent for the study, or have moderate or severe cognitive impairment;
  • Have difficulty ambulating as evidenced by any one of the following:
  • Difficulty climbing 10 steps without resting;
  • Restricted to a wheelchair
  • Have difficulty performing basic activities of daily living;
  • Have had treatment for cancer in the prior 3 years;
  • Have history of cachexia;
  • Have a history of heart failure;
  • Have a permanent pacemaker in situ (due to magnetic resonance scanning);
  • Have an implanted cardioverter-defibrillator (ICD) in situ;
  • Have had myocardial infarction within the last 6 months;
  • Have any of the following chronic health conditions: peripheral arterial disease prostate cancer, rheumatoid arthritis, autoimmune myositis, chronic obstructive pulmonary disease, and asthma;
  • Are receiving therapy with corticosteroids or immunosuppressants.
  • Are taking direct insulin sensitizers (PPAR-gamma agonists, or thiazolidinediones).

Treatment and study plan

Primary outcomes

  1. To explore the correlation of sarcopenia and obesity on insulin resistance

    Time frame: 2 years

Secondary outcomes

  1. To explore the correlation between muscle strength and memory loss

    Time frame: 2 years

  2. To explore the correlation of sarcopenic obesity and glucometabolic and cardiovascular risk.

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

University of Central Florida

Other

Registry information

Official study title

Sarcopenic Obesity as Risk Factor for Insulin Resistance in the Elderly

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 16, 2023
Registry last updated
Oct 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.